LILRB4 and myeloid sarcoma: Additionally, recombinant human LILRB4 protein has shown promise in MS mouse models by suppressing proinflammatory cytokine release and inhibiting pathogenic Th1 and Th17 cell proliferation, preventing autoimmune neuroinflammation and suggesting a potential treatment modality for MS 289.